191. ウェルナー症候群 Werner syndrome Clinical trials / Disease details
臨床試験数 : 3 / 薬物数 : 4 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs031190141 | 19/03/2021 | 27/11/2019 | Cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome | Prospective, single-center, cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome - EMPOWER | Werner syndrome Werner syndrome;C16.320.925 / C18.452.284.960 | Subjects ingest oral capsules of NR (nicotinamide riboside) once daily (total daily dose: nicotinamide riboside 1000 mg). | Yokote Koutaro | NULL | Recruiting | >= 20age old | Not applicable | Both | 30 | Phase 1-2 | Japan |